The 2024 conference has 28 late-breakers plus plenty of basic and population science. More than anything, it’s a celebration.

Completed dosing of 115 participants in a bioavailability and bioequivalence (BA/BE) clinical trial in Australia for IHL-42X, an investigational treatment for obstructive sleep apnea in July 2024.

Inc. ( an integrated pharmaceutical company dedicated to the worldwide development and commercialization of impactful ...